​

Roivant Sciences (ROIV) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChartTranscripts

ROIV Stock Forecast

Roivant Sciences (ROIV) stock forecast, based on 14 Wall Street analysts, predicts a 12-month average price target of $31.50, with a high of $34.00 and a low of $30.00. This represents a 10.33% increase from the last price of $28.55.

$10 $15 $20 $25 $30 $35 High: $34 Avg: $31.5 Low: $30 Last Closed Price: $28.55

ROIV Stock Rating

Roivant Sciences stock's rating consensus is Buy, based on 14 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 13 Buy (92.86%), 1 Hold (7.14%), 0 Sell (0.00%), and 0 Strong Sell (0.00%).

Buy
Total 14 0 1 13 Strong Sell Sell Hold Buy Strong Buy

ROIV Price Target Upside V Benchmarks

TypeNameUpside
StockRoivant Sciences10.33%
SectorHealthcare Stocks 15.45%
IndustryBiotech Stocks 41.48%

Price Target Trends

1M3M12M
# Anlaysts1612
Avg Price Target$34.00$31.17$27.33
Last Closing Price$28.55$28.55$28.55
Upside/Downside19.09%9.18%-4.27%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Mar, 26291--12
Feb, 26291--12
Jan, 26291--12
Dec, 25291--12
Nov, 25381--12
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Mar 04, 2026Douglas TsaoH.C. Wainwright$34.00$28.8118.01%19.09%
Feb 10, 2026H.C. Wainwright$33.00$27.6719.26%15.59%
Feb 09, 2026Jefferies$30.00$26.4513.42%5.08%
Feb 09, 2026Guggenheim$30.00$25.8216.19%5.08%
Dec 18, 2025Guggenheim$28.00$22.3025.56%-1.93%
Dec 15, 2025David RisingerLeerink Partners$32.00$22.1044.80%12.08%
Dec 12, 2025H.C. Wainwright$26.00$21.4721.10%-8.93%
Nov 14, 2025Yastin SunejaGuggenheim$25.00$20.5621.60%-12.43%
Nov 11, 2025David RisingerLeerink Partners$29.00$21.1736.99%1.58%
Sep 18, 2025Jefferies$20.00$15.4729.28%-29.95%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Mar 04, 2026Cowen & Co.BuyBuyhold
Mar 04, 2026H.C. WainwrightBuyBuyhold
Mar 03, 2026JefferiesBuyBuyhold
Feb 10, 2026CitigroupBuyBuyhold
Feb 10, 2026H.C. WainwrightBuyBuyhold
Feb 09, 2026JefferiesBuyBuyhold
Feb 09, 2026GuggenheimBuyBuyhold
Feb 07, 2026Cowen & Co.BuyBuyhold
Dec 18, 2025GuggenheimBuyBuyhold
Dec 15, 2025Leerink PartnersOutperformOutperformhold

Financial Forecast

EPS Forecast

$-3 $-2 $-1 $0 $1 $2 $3 $4 $5 $6 Mar 23 Mar 24 Mar 24 Mar 25 Mar 26 Mar 27 Mar 28 Mar 29
Mar 23Mar 24Mar 25Mar 26Mar 27Mar 28Mar 29
Reported$-1.42$5.55-----
Avg Forecast$-1.59$5.22$-0.77$-1.09$-1.07$-0.47$0.20
High Forecast$-0.73$5.41$-0.72$-0.81$-0.82$-0.22$0.33
Low Forecast$-2.63$4.98$-0.81$-1.29$-1.39$-0.77$0.09
Surprise %-10.69%6.32%-----

Revenue Forecast

$0 $500M $1B $2B $2B $3B Mar 23 Mar 24 Mar 24 Mar 25 Mar 26 Mar 27 Mar 28 Mar 29
Mar 23Mar 24Mar 25Mar 26Mar 27Mar 28Mar 29
Reported$61.28M$124.80M-----
Avg Forecast$52.28M$181.74M$92.10M$34.74M$61.48M$762.32M$1.57B
High Forecast$78.79M$193.36M$139.48M$59.09M$92.67M$1.15B$2.37B
Low Forecast$30.60M$176.37M$56.33M$17.27M$35.98M$446.16M$920.09M
Surprise %17.22%-31.33%-----

Net Income Forecast

$-3B $-1B $300M $2B $3B $5B Mar 23 Mar 24 Mar 24 Mar 25 Mar 26 Mar 27 Mar 28 Mar 29
Mar 23Mar 24Mar 25Mar 26Mar 27Mar 28Mar 29
Reported$-1.01B$4.35B-----
Avg Forecast$-1.32B$4.35B$-605.08M$-804.05M$-911.26M$-387.83M$163.44M
High Forecast$-608.11M$4.50B$-596.22M$-672.44M$-682.96M$-178.73M$271.22M
Low Forecast$-2.19B$4.14B$-670.75M$-1.07B$-1.15B$-643.57M$75.32M
Surprise %-23.53%-0.07%-----

ROIV Forecast FAQ

Is Roivant Sciences stock a buy?

Roivant Sciences stock has a consensus rating of Buy, based on 14 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 13 Buy, 1 Hold, 0 Sell, and 0 Strong Sell, reflecting a consensus that Roivant Sciences is a favorable investment for most analysts.

What is Roivant Sciences's price target?

Roivant Sciences's price target, set by 14 Wall Street analysts, averages $31.5 over the next 12 months. The price target range spans from $30 at the low end to $34 at the high end, suggesting a potential 10.33% change from the previous closing price of $28.55.

How does Roivant Sciences stock forecast compare to its benchmarks?

Roivant Sciences's stock forecast shows a 10.33% upside, underperforming the average forecast for the healthcare stocks sector (15.45%) and underperforming the biotech stocks industry (41.48%).

What is the breakdown of analyst ratings for Roivant Sciences over the past three months?

  • March 2026: 16.67% Strong Buy, 75.00% Buy, 8.33% Hold, 0% Sell, 0% Strong Sell.
  • February 2026: 16.67% Strong Buy, 75.00% Buy, 8.33% Hold, 0% Sell, 0% Strong Sell.
  • January 2026: 16.67% Strong Buy, 75.00% Buy, 8.33% Hold, 0% Sell, 0% Strong Sell.

What is Roivant Sciences’s EPS forecast?

Roivant Sciences's average annual EPS forecast for its fiscal year ending in March 2025 is $-0.77, marking a -113.87% decrease from the reported $5.55 in 2024. Estimates for the following years are $-1.09 in 2026, $-1.07 in 2027, $-0.47 in 2028, and $0.2 in 2029.

What is Roivant Sciences’s revenue forecast?

Roivant Sciences's average annual revenue forecast for its fiscal year ending in March 2025 is $92.1M, reflecting a -26.20% decrease from the reported $124.8M in 2024. The forecast for 2026 is $34.74M, followed by $61.48M for 2027, $762.32M for 2028, and $1.57B for 2029.

What is Roivant Sciences’s net income forecast?

Roivant Sciences's net income forecast for the fiscal year ending in March 2025 stands at $-605M, representing a -113.91% decrease from the reported $4.35B in 2024. Projections indicate $-804M in 2026, $-911M in 2027, $-388M in 2028, and $163.44M in 2029.